OncoMatch

OncoMatch/Clinical Trials/NCT07677267

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Is NCT07677267 recruiting? Yes, currently enrolling (Sep 2026).

RecruitingNovartis PharmaceuticalsNCT07677267Data as of Sep 2026

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Demographics

Ages ≤ 115
Male only

Prior therapy

Must have received: Lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617)

Evidence of 177Lu-PSMA-617 use on or after 01 January 2021

Must have received: androgen receptor pathway inhibitor

Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617

Must have received: taxane

Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Novartis · East Hanover, New Jersey

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07677267 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received Lutetium-177 vipivotide tetraxetan and androgen receptor pathway inhibitor.

Is there an age limit?

Yes. Patients must be 115 years or younger.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify